Literature DB >> 7979858

Antibody against oxidized low-density lipoprotein predicting myocardial infarction.

M Puurunen1, M Mänttäri, V Manninen, L Tenkanen, G Alfthan, C Ehnholm, O Vaarala, K Aho, T Palosuo.   

Abstract

BACKGROUND: Oxidation of low-density lipoprotein is believed to be an important step in the pathogenesis of atherosclerosis. The purpose of the present study was to determine whether antibody against oxidized low-density lipoprotein, reported to be associated with the progression of carotid atherosclerosis, is predictive of cardiac death and nonfatal myocardial infarction.
METHODS: Serum samples from 135 cases and their controls, drawn at entry from middle-aged dyslipidemic men participating in the Helsinki Heart Study, a 5-year coronary primary prevention trial with gemfibrozil, were tested for immunoglobulin G class antibodies against oxidized low-density lipoprotein by enzyme-linked immunosorbent assay.
RESULTS: The mean antibody level, expressed in optical density units, was significantly higher in cases than in controls (0.412 vs 0.356, P = .002). After adjustment for age, smoking, blood pressure, and high-density lipoprotein cholesterol level, there was a 2.5-fold increased risk (95% confidence interval, 1.3 to 4.9) of a cardiac end point in the highest tertile of antibody level vs the lowest tertile (P = .005 for trend).
CONCLUSIONS: Elevated levels of antibodies against oxidized low-density lipoprotein were predictive of myocardial infarction. The effect was independent of low-density lipoprotein cholesterol levels, and the joint effect was additive. Elevated antibody levels modified the effects of classic coronary risk factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979858

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  31 in total

1.  Inflammation-mediated rheumatic diseases and atherosclerosis.

Authors:  S Manzi; M C Wasko
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

Review 2.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients.

Authors:  Eva C Fernvik; Daniel F J Ketelhuth; Momtchilo Russo; Magnus Gidlund
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

4.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

Review 6.  Vaccines for cholesterol management.

Authors:  Charles W Rittershaus
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

7.  Expression of low-density lipoprotein receptors in peripheral blood and tonsil B lymphocytes.

Authors:  J B De Sanctis; I Blanca; H Rivera; N E Bianco
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Clinical significance of antibodies against oxidised low density lipoprotein in early RA.

Authors:  L Paimela; T Helve; M Leirisalo-Repo; O Vaarala; G Alfthan; T Palosuo; K Aho
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

9.  Anti-oxidized low-density lipoprotein antibodies in chronic heart failure.

Authors:  Gideon Charach; Alexander Rabinovich; Ori Argov; Moshe Weintraub; Lior Charach; Oded Ayzenberg; Jacob George
Journal:  World J Cardiol       Date:  2012-11-26

10.  Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.

Authors:  Igor A Sobenin; Vasily P Karagodin; Alexandra Capital A Cyrillic Melnichenko; Yuri V Bobryshev; Alexander N Orekhov
Journal:  J Clin Immunol       Date:  2012-10-17       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.